{"category":{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-03T05:53:03.969Z","updated_at":"2026-09-03T05:53:03.969Z","example":false,"profile_url":"/industries/drug-discovery","is_stub":true,"member_count":35,"member_counts":{"company":35}},"members":[{"listing_type":"company","name":"ImpriMed","slug":"imprimed","tagline":"AI-driven precision medicine for oncology, veterinary, and pharma CRO","description":"ImpriMed is an AI precision-medicine company that predicts patient-specific drug responses for oncology. It began in veterinary cancer care (canine and feline blood cancers) and also serves human oncology and pharmaceutical CRO use cases with live-cell drug-response testing and precision analytics. Public site: imprimedicine.com.","url":"https://www.imprimedicine.com/","is_stealth":false,"normalized_domain":"imprimedicine.com","normalized_url_key":"imprimedicine.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/61424e4c194b4329bd3c0096/6a7fb90095ffed595d081960_ImpriMed_Logo_dark.png","links":[{"label":"X / Twitter","url":"https://x.com/imprimedicine","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/imprimed-inc","platform":"linkedin"},{"label":"YouTube","url":"https://www.youtube.com/channel/UCC6uyRplSyJcFWE0NldiF4Q","platform":"youtube"},{"label":"Instagram","url":"https://www.instagram.com/imprimedicine","platform":"instagram"},{"label":"Facebook","url":"https://www.facebook.com/imprimedicine","platform":"facebook"}],"entry_points":[{"kind":"homepage","url":"https://www.imprimedicine.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.imprimedicine.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2f338f37-f051-40b9-bdf1-ff76d7555985"},"categories":["Biotech","Healthcare","AI","Drug Discovery"],"stage":"series-a","founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/imprimedicine","github":null,"linkedin":"https://www.linkedin.com/company/imprimed-inc","contact_email":null,"added_at":"2026-09-20T17:07:23.828Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T17:07:23.828Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-20T17:07:23.828Z","updated_at":"2026-09-20T17:07:23.828Z"}},{"listing_type":"company","name":"Anew Labs","slug":"anew-labs","tagline":"AI drug discovery combining models with experimental science","description":"Anew Labs (also referred to as Anew Therapeutics) is an AI pharmaceutical company applying machine learning to drug discovery. Its public platform work spans structure prediction, dynamics-aware sampling, all-atom generative modeling, antibody design, and scientific reasoning models, combined with experimental science and drug-discovery expertise. The company lists offices in Shanghai, San Francisco, and Singapore.","url":"https://anewbt.com/","is_stealth":false,"normalized_domain":"anewbt.com","normalized_url_key":"anewbt.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://anewbt.com/assets/anew-logo-en-long.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/anew-labs","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://anewbt.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://anewbt.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"e9817002-ecc6-4b97-ba5b-ec6d37f12c85"},"categories":["Biotech","AI","Healthcare","Drug Discovery","B2B"],"stage":"growth","founded_year":null,"location":"Shanghai / San Francisco / Singapore","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/anew-labs","contact_email":null,"added_at":"2026-09-16T08:10:13.716Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-20T14:09:14.395Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-16T08:10:13.716Z","updated_at":"2026-09-16T08:10:13.716Z"}},{"listing_type":"company","name":"Big Picture Bio","slug":"big-picture-bio","tagline":"World models for cancer combination therapies","description":"Big Picture Bio is a UK therapeutics company using generative world models to identify, design, and optimise cancer drug combinations. The platform models how tumours, immune cells, and surrounding tissue interact so teams can prioritise combinations for wet-lab validation. Founded by Deep Science Ventures veterans and based in the UK.","url":"https://bigpicturebio.com/","is_stealth":false,"normalized_domain":"bigpicturebio.com","normalized_url_key":"bigpicturebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bigpicturebio.com/img/favicon-180.png","links":[{"label":"X / Twitter","url":"https://x.com/bigpicturebio","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/big-picture-bio","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://bigpicturebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://bigpicturebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Kerstin Papenfuss","role":"CEO and co-founder","person_slug":"kerstin-papenfuss-1dshmb8zovifi","bio":null,"location":null,"links":[]},{"name":"Mark Hammond","role":"CTO and co-founder","person_slug":"mark-hammond-1kif1ipssf4v2","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"415b41d1-52be-45bb-ae8a-51a1e474bbf5"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-18T11:23:35.924Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T11:23:35.924Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T11:23:35.924Z","updated_at":"2026-09-18T11:23:35.924Z"}},{"listing_type":"company","name":"Mithrl","slug":"mithrl","tagline":"Biomedical world model for scientific decision-making in biopharma","description":"Mithrl builds a biomedical AI platform that grounds R&D decisions in validated biology. Its Mithrl-1 platform combines a proprietary biomedical world model with an agentic harness for model routing and orchestration, and is designed to deploy inside customer environments alongside proprietary data. The company says the platform helps teams identify targets and biomarkers, interpret results in biological context, and produce auditable insights. In September 2026 it announced a $20M Series A led by Obvious Ventures, with participation from Headline, AGI House, and pharma executives. Co-founders include CEO Vivek Adarsh and CTO Shara Balakrishnan.","url":"https://www.mithrl.com/","is_stealth":false,"normalized_domain":"mithrl.com","normalized_url_key":"mithrl.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.sanity.io/images/vg07j0q0/production/1cfb562f53dc8a8cbdf6a7e9dea06844204a9313-1200x630.png?w=1200&h=630&fit=max&auto=format","links":[{"label":"X","url":"https://x.com/mithrl_ai","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/mithrl-ai","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.mithrl.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.mithrl.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Vivek Adarsh","role":"Co-Founder & CEO","person_slug":"vivek-adarsh-0ulss458a91t5","bio":null,"location":null,"links":[]},{"name":"Shara Balakrishnan","role":"Co-Founder & CTO","person_slug":"shara-balakrishnan-3c93nookrmxuw","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"ce733a4e-da29-4832-874e-056ad6429606"},"categories":["Biotech","AI","Healthcare","Drug Discovery","Enterprise Software"],"stage":"series-a","founded_year":null,"location":null,"pricing":null,"twitter":"https://x.com/mithrl_ai","github":null,"linkedin":"https://www.linkedin.com/company/mithrl-ai","contact_email":null,"added_at":"2026-09-17T17:21:43.885Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-17T17:21:43.885Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"enterprise-software","name":"Enterprise Software","note":null,"profile_url":"/industries/enterprise-software"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-17T17:21:43.885Z","updated_at":"2026-09-17T17:21:43.885Z"}},{"listing_type":"company","name":"Polyphron","slug":"polyphron","tagline":"AI-guided tissue foundry for artificial human biology","description":"Polyphron is a New York biotech building an autonomous tissue foundry that manufactures and simulates donor-diverse human tissues. Its platform combines physical tissue production from stem cells with a simulation layer intended to help test therapeutic hypotheses against living human biology. The company publicly describes products including a Tissue Foundry and Tissue World Model, and announced a $20M seed round led by Quiet Capital (with Gradient, Haystack, and Compound) in September 2026. Founders include CEO Matthew Osman, CSO Fabio Boniolo, and Chief AI Scientist Vinh Q. Tran.","url":"https://www.polyphron.com/","is_stealth":false,"normalized_domain":"polyphron.com","normalized_url_key":"polyphron.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://cdn.prod.website-files.com/6aa26324ee6b1b267c6abb67/6aa973048a629ba43946ab25_Group%201538233483%20(2).png","links":[{"label":"X","url":"https://x.com/polyphron","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/polyphron","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://www.polyphron.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.polyphron.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Matthew Osman","role":"CEO","person_slug":"matthew-osman-0tloed29cudra","bio":null,"location":null,"links":[]},{"name":"Fabio Boniolo","role":"CSO","person_slug":"fabio-boniolo-2k4l3n99lsqzl","bio":null,"location":null,"links":[]},{"name":"Vinh Q. Tran","role":"Chief AI Scientist","person_slug":"vinh-q-tran-2o1cvgloeii6p","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"1372eeda-4bb2-4c51-873c-6e824d554cef"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":"seed","founded_year":null,"location":"New York, NY, USA","pricing":null,"twitter":"https://x.com/polyphron","github":null,"linkedin":"https://www.linkedin.com/company/polyphron","contact_email":null,"added_at":"2026-09-17T17:21:38.118Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-17T17:21:38.118Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-17T17:21:38.118Z","updated_at":"2026-09-17T17:21:38.118Z"}},{"listing_type":"company","name":"Halmos Labs","slug":"halmos-labs","tagline":"Automated biotech R&D for maximum information per experiment","description":"Halmos Labs is a Lund, Sweden biotech company in Y Combinator Fall 2026. It builds automated biotech R&D focused on validity and interpretability, running research and simulations from wet-lab experiment design to cancer vaccine manufacturing. Founded in 2026 by Mattias Akke (CEO) and Linus von Ekensteen Löfgren (CTO). Its first product is Halmos Bio at https://halmoslabs.com/.","url":"https://halmoslabs.com/","is_stealth":false,"normalized_domain":"halmoslabs.com","normalized_url_key":"halmoslabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://halmoslabs.com/halmos-symbol.png","links":[{"label":"Y Combinator","url":"https://www.ycombinator.com/companies/halmos-labs"}],"entry_points":[{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://halmoslabs.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Mattias Akke","role":"Founder and CEO","person_slug":"mattias-akke-3dl5m9duqb1h9","bio":null,"location":null,"links":[]},{"name":"Linus von Ekensteen Löfgren","role":"Founder and CTO","person_slug":"linus-von-ekensteen-l-fgren-2xn364093azto","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"63b5073c-4d03-4212-a6cd-7e13d92739af"},"categories":["Biotech","AI","Healthcare","Drug Discovery"],"stage":"pre-seed","founded_year":2026,"location":"Lund, Sweden","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-12T08:08:19.611Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-12T08:08:19.611Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-12T08:08:19.611Z","updated_at":"2026-09-12T08:08:19.611Z"}},{"listing_type":"company","name":"Pixeom","slug":"pixeom","tagline":"Chemical vision AI for molecular structure analysis in drug discovery","description":"Pixeom is an Oita University-originated startup developing chemical vision AI that converts three-dimensional molecular structures into representations AI models can learn from, aimed at drug discovery and chemical research. The company publicly announced a seed round led by Lifetime Ventures.","url":"https://pixeom.jp/","is_stealth":false,"normalized_domain":"pixeom.jp","normalized_url_key":"pixeom.jp","parent_slug":null,"parent":null,"type_data":{},"logo":"https://pixeom.jp/wp-content/uploads/2025/07/cropped-pixeom-logo-192x192.png","links":[],"entry_points":[{"kind":"homepage","url":"https://pixeom.jp/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://pixeom.jp/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"name":"Shigeru Matsuoka","role":"Representative Director","person_slug":"shigeru-matsuoka-3c35s0oz6jdxh","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"5b3692d0-e02b-4cfb-ada9-eb0c448c2b46"},"categories":["AI","Biotech","Drug Discovery","Deep Tech"],"stage":"seed","founded_year":null,"location":"Oita, Japan","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-09T14:10:33.191Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-09T14:10:33.191Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-09T14:10:33.191Z","updated_at":"2026-09-09T14:10:33.191Z"}},{"listing_type":"company","name":"Atlas Discovery","slug":"atlas-discovery","tagline":"AI-native pharma company","description":"AI-native pharma company\n\nAtlas Discovery is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://atlasdiscovery.bio/","is_stealth":false,"normalized_domain":"atlasdiscovery.bio","normalized_url_key":"atlasdiscovery.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/6e6c174c3a8e56844bf81efbc8b8532b4e509f73.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/atlas-discovery","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://atlasdiscovery.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://atlasdiscovery.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Drug discovery","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:28:33.118Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","AI-powered Drug Discovery","Drug discovery","Biotechnology"],"one_liner_for_search":"Atlas Discovery — AI-native pharma company (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Rhizome Bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:28:33.118Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:28:33.118Z","updated_at":"2026-09-03T08:28:33.118Z"}},{"listing_type":"company","name":"Anto Biosciences","slug":"anto-biosciences","tagline":"A Foundation Model for Microbial Communities.","description":"Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. \n\nFounded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature.\n\nAnto Biosciences is a Y Combinator company (Fall 2025). YC-listed status: Active.","url":"https://anto.bio/","is_stealth":false,"normalized_domain":"anto.bio","normalized_url_key":"anto.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/83f56c369ac0fb5e70438516e774b8603717940a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/anto-biosciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://anto.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://anto.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Artificial Intelligence","Generative AI","Biotech","Genomics","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:16:14.842Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Fall 2025","Artificial Intelligence","Generative AI","Biotech","Genomics","Drug discovery"],"one_liner_for_search":"Anto Biosciences — A Foundation Model for Microbial Communities. (Y Combinator Fall 2025)","canonical_facts":["Y Combinator batch: Fall 2025","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare","Former names: Anto","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:16:14.842Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"generative-ai","name":"Generative AI","note":null,"profile_url":"/industries/generative-ai"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:16:14.842Z","updated_at":"2026-09-03T08:16:14.842Z"}},{"listing_type":"company","name":"Biocartesian","slug":"biocartesian","tagline":"Converting biology into digital molecular maps","description":"Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.\n\nBiocartesian is a Y Combinator company (Summer 2024). YC-listed status: Active.","url":"https://www.biocartesian.com/","is_stealth":false,"normalized_domain":"biocartesian.com","normalized_url_key":"biocartesian.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/91093b7c8dbe1ed84a73aa4907b878fc5b0f52bf.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/biocartesian","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.biocartesian.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.biocartesian.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Hard Tech","B2B","Biotech","Diagnostics","Drug discovery"],"stage":null,"founded_year":null,"location":"Philadelphia, PA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:50:25.470Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2024","Hard Tech","B2B","Biotech","Diagnostics","Drug discovery"],"one_liner_for_search":"Biocartesian — Converting biology into digital molecular maps (Y Combinator Summer 2024)","canonical_facts":["Y Combinator batch: Summer 2024","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: coordna bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:50:25.470Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"hard-tech","name":"Hard Tech","note":null,"profile_url":"/industries/hard-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:50:25.470Z","updated_at":"2026-09-03T07:50:25.470Z"}},{"listing_type":"company","name":"Ångström AI","slug":"angstrom-ai","tagline":"Gen AI molecular simulations that reproduce wetlab results","description":"Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models.\n\nOur Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies.\n\nSince joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.\n\nÅngström AI is a Y Combinator company (Summer 2024). YC-listed status: Active.","url":"https://angstrom-ai.com/","is_stealth":false,"normalized_domain":"angstrom-ai.com","normalized_url_key":"angstrom-ai.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/d66ae246dae1ca35e8275f53019cac07d3259c99.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/angstrom-ai","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://angstrom-ai.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://angstrom-ai.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Artificial Intelligence","Biotech","Drug discovery","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:46:07.349Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2024","AI-powered Drug Discovery","Artificial Intelligence","Biotech","Drug discovery","AI"],"one_liner_for_search":"Ångström AI — Gen AI molecular simulations that reproduce wetlab results (Y Combinator Summer 2024)","canonical_facts":["Y Combinator batch: Summer 2024","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Angstrom AI","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:46:07.349Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:46:07.349Z","updated_at":"2026-09-03T07:46:07.349Z"}},{"listing_type":"company","name":"ParcelBio","slug":"parcelbio","tagline":"Elevated mRNA for transformative medicines.","description":"ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.\n\nParcelBio is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://parcelbio.com/","is_stealth":false,"normalized_domain":"parcelbio.com","normalized_url_key":"parcelbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/74f762bd0f8856c1dbe4d716afa6585e44f03870.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/parcelbio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://parcelbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://parcelbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Synthetic Biology","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:46:05.163Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Gene Therapy","Synthetic Biology","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"ParcelBio — Elevated mRNA for transformative medicines. (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Parcel Therapuetics, Parcel Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:46:05.163Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:46:05.163Z","updated_at":"2026-09-03T07:46:05.163Z"}},{"listing_type":"company","name":"Eris Biotech","slug":"eris-biotech","tagline":"Our drugs engage the immune system to fight tumors","description":"We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.\n\nEris Biotech is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.erisbio.com/","is_stealth":false,"normalized_domain":"erisbio.com","normalized_url_key":"erisbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eris-biotech","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.erisbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.erisbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"Lehi, UT, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:44:18.257Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Biotech","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Eris Biotech — Our drugs engage the immune system to fight tumors (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:44:18.257Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:44:18.257Z","updated_at":"2026-09-03T07:44:18.257Z"}},{"listing_type":"company","name":"Velorum Therapeutics","slug":"velorum-therapeutics","tagline":"Breakthrough medicines unlocking the biology of heme","description":"Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.\n\nVelorum Therapeutics is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.velorumtx.com/","is_stealth":false,"normalized_domain":"velorumtx.com","normalized_url_key":"velorumtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/velorum-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.velorumtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.velorumtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:43:18.066Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Biotech","Healthcare","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Velorum Therapeutics — Breakthrough medicines unlocking the biology of heme (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:43:18.066Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:43:18.066Z","updated_at":"2026-09-03T07:43:18.066Z"}},{"listing_type":"company","name":"ACX","slug":"acx","tagline":"Next-generation biocides for sustainable agriculture at scale","description":"ACX is developing a new standard for precision agriculture technologies by providing sustainable, eco-friendly alternatives to chemical pesticides. Our mission is to transform agriculture through sustainable biological crop protection that increases yields while safeguarding the environment, farmers, and consumers.\n\nACX is a Y Combinator company (Summer 2024). YC-listed status: Active.","url":"https://www.acxtherapeutics.com/","is_stealth":false,"normalized_domain":"acxtherapeutics.com","normalized_url_key":"acxtherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/9bb37e7a5bced1e654bfc08df7f21868e28bd64c.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/acx","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.acxtherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.acxtherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Industrial Bio","Synthetic Biology","Biotech","Agriculture","Drug discovery"],"stage":null,"founded_year":null,"location":"New York City, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:42:23.582Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2024","Synthetic Biology","Biotech","Healthcare","Agriculture","Drug discovery"],"one_liner_for_search":"ACX — Next-generation biocides for sustainable agriculture at scale (Y Combinator Summer 2024)","canonical_facts":["Y Combinator batch: Summer 2024","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Industrial Bio","Former names: AcX Therapeutics, AcX","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:42:23.582Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"agriculture","name":"Agriculture","note":null,"profile_url":"/industries/agriculture"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"industrial-bio","name":"Industrial Bio","note":null,"profile_url":"/industries/industrial-bio"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:42:23.582Z","updated_at":"2026-09-03T07:42:23.582Z"}},{"listing_type":"company","name":"Invitris","slug":"invitris","tagline":"Creating new protein-based drugs at scale","description":"Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.\n\nOur killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.\n\nInvitris is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://www.invitris.com/","is_stealth":false,"normalized_domain":"invitris.com","normalized_url_key":"invitris.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b31c6e14e61e0a7e292383c88d7094914a492565.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/invitris","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.invitris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.invitris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Nanotechnology","Drug discovery"],"stage":null,"founded_year":null,"location":"Munich, BY, Germany","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:16.195Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Biotech","Nanotechnology","Drug discovery"],"one_liner_for_search":"Invitris — Creating new protein-based drugs at scale (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): Germany, Europe, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:16.195Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"nanotechnology","name":"Nanotechnology","note":null,"profile_url":"/industries/nanotechnology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:16.195Z","updated_at":"2026-09-03T07:28:16.195Z"}},{"listing_type":"company","name":"Adventris Pharmaceuticals","slug":"adventris-pharmaceuticals","tagline":"Adventris makes cancer vaccines","description":"Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first \"off-the-shelf\" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.\n\nIf you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com\n\nAdventris Pharmaceuticals is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://www.adventris.com/","is_stealth":false,"normalized_domain":"adventris.com","normalized_url_key":"adventris.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/5c8bb0a987c29df94410bb9cc6ab7db9eb0d6478.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/adventris-pharmaceuticals","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.adventris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.adventris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Therapeutics","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"Baltimore, MD, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:14.694Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Biotech","Healthcare","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Adventris Pharmaceuticals — Adventris makes cancer vaccines (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 7","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Elimivax","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:14.694Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:14.694Z","updated_at":"2026-09-03T07:28:14.694Z"}},{"listing_type":"company","name":"Relevium Medical","slug":"relevium-medical","tagline":"Platform injectable gel based therapeutic for osteoarthritis","description":"Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease.\nRight now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. \nTo date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. \nInsurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity.\nThis platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.\n\nRelevium Medical is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://relevium-medical.com/","is_stealth":false,"normalized_domain":"relevium-medical.com","normalized_url_key":"relevium-medical.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/fe3f53ef710ec5758d984168f33594337d5df8ae.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/relevium-medical","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://relevium-medical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://relevium-medical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Medical Devices","Drug discovery"],"stage":null,"founded_year":null,"location":"Galway, County Galway, Ireland","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:19:15.666Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Medical Devices","Healthcare","Therapeutics","Drug discovery"],"one_liner_for_search":"Relevium Medical — Platform injectable gel based therapeutic for osteoarthritis (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Relevium, ReleviumBio","Regions (per YC): Ireland, Europe"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:19:15.666Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:19:15.666Z","updated_at":"2026-09-03T07:19:15.666Z"}},{"listing_type":"company","name":"Origami Therapeutics, Inc.","slug":"origami-therapeutics-inc","tagline":"Oral drugs to halt neurodegeneration","description":"Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.\n\nOrigami Therapeutics, Inc. is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"https://origamitherapeutics.com/","is_stealth":false,"normalized_domain":"origamitherapeutics.com","normalized_url_key":"origamitherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ec01151ea9fbf839d64b9d2a17dedc03fb322eeb.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/origami-therapeutics-inc","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://origamitherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://origamitherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Diego, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:10:33.522Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Origami Therapeutics, Inc. — Oral drugs to halt neurodegeneration (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:10:33.522Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:10:33.522Z","updated_at":"2026-09-03T07:10:33.522Z"}},{"listing_type":"company","name":"Alixia","slug":"alixia","tagline":"Targeting the Tumor Ecosystem to address cancer drug resistance.","description":"Our compounds disrupt the metabolic and\ninflammatory triggers in both cancer and quasi-cancerous\ncells in the tumor microenvironment. By impacting multiple cell\ntypes, we are enabling effective, lasting cancer treatments.\n\nAlixia is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"https://www.alixia.com/","is_stealth":false,"normalized_domain":"alixia.com","normalized_url_key":"alixia.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/alixia","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.alixia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.alixia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:03:09.927Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Biotech","Therapeutics","Drug discovery","Oncology","Biotechnology"],"one_liner_for_search":"Alixia — Targeting the Tumor Ecosystem to address cancer drug resistance. (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Guided Clarity","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:03:09.927Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:03:09.927Z","updated_at":"2026-09-03T07:03:09.927Z"}},{"listing_type":"company","name":"Harmonic Discovery","slug":"harmonic-discovery","tagline":"Multi-targeted therapeutics to treat complex diseases","description":"We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. \n\nWe are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines.\n\nHarmonic Discovery is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://harmonicdiscovery.com/","is_stealth":false,"normalized_domain":"harmonicdiscovery.com","normalized_url_key":"harmonicdiscovery.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/dbebdea5cbd5fee23eff97b4d514d27fb9652ed0.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/harmonic-discovery","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://harmonicdiscovery.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://harmonicdiscovery.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"New York City, NY, USA; New York, NY, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:55:22.473Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","AI-powered Drug Discovery","Biotech","Healthcare","Drug discovery"],"one_liner_for_search":"Harmonic Discovery — Multi-targeted therapeutics to treat complex diseases (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 8","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:55:22.473Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:55:22.473Z","updated_at":"2026-09-03T06:55:22.473Z"}},{"listing_type":"company","name":"Talus Bio","slug":"talus-bio","tagline":"Discovering drugs that target the DNA regulome","description":"We have built a platform that enables drug discovery and development for previously undruggable genome regulators (\"the regulome\"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.\n\nTalus Bio is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://www.talus.bio/","is_stealth":false,"normalized_domain":"talus.bio","normalized_url_key":"talus.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/6677b768e2a0c2a30de4f32fc3f4f2dce1baea6a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/talus-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.talus.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.talus.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Genomics","Drug discovery"],"stage":null,"founded_year":null,"location":"Seattle, WA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:48:19.888Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Biotech","Genomics","Drug discovery"],"one_liner_for_search":"Talus Bio — Discovering drugs that target the DNA regulome (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 16","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:48:19.888Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:48:19.888Z","updated_at":"2026-09-03T06:48:19.888Z"}},{"listing_type":"company","name":"Valink Therapeutics","slug":"valink-therapeutics","tagline":"Discovering bispecific antibody drug-conjugates (BsADC) against cancer","description":"Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.\n\nValink Therapeutics is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.valinktx.com/","is_stealth":false,"normalized_domain":"valinktx.com","normalized_url_key":"valinktx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/4fdbac90b07fa4233736c11be944db20adb49e3b.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/valink-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.valinktx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.valinktx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:40:15.298Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Valink Therapeutics — Discovering bispecific antibody drug-conjugates (BsADC) against cancer (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: SpyCombinator, LiliumX","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:40:15.298Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:40:15.298Z","updated_at":"2026-09-03T06:40:15.298Z"}},{"listing_type":"company","name":"Serna Bio","slug":"serna-bio","tagline":"Genetic Medicine with Small Molecules","description":"Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.\n\nSerna Bio is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.serna.bio/","is_stealth":false,"normalized_domain":"serna.bio","normalized_url_key":"serna.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e5c345ecf4dc0bf6d96b3cb2f1e7485d78c1449d.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/serna-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.serna.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.serna.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"Ontario, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:37:36.367Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Biotech","Drug discovery"],"one_liner_for_search":"Serna Bio — Genetic Medicine with Small Molecules (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Ladder Therapeutics (LTX)","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:37:36.367Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:37:36.367Z","updated_at":"2026-09-03T06:37:36.367Z"}},{"listing_type":"company","name":"Algen Biotechnologies","slug":"algen-biotechnologies","tagline":"Using CRISPR to find treatments for cancer and inflammation","description":"Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.\n\nAlgen Biotechnologies is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.algenbio.com/","is_stealth":false,"normalized_domain":"algenbio.com","normalized_url_key":"algenbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/41218b0dee65a988940509b3fe258626c5137590.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/algen-biotechnologies","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.algenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.algenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","CRISPR","Biotech","Therapeutics","Drug discovery","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:32:33.310Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","CRISPR","Biotech","Therapeutics","Drug discovery","AI"],"one_liner_for_search":"Algen Biotechnologies — Using CRISPR to find treatments for cancer and inflammation (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Algen Biotechnologies, Inc.","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:32:33.310Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:32:33.310Z","updated_at":"2026-09-03T06:32:33.310Z"}},{"listing_type":"company","name":"Altay Therapeutics","slug":"altay-therapeutics","tagline":"Altay develops disease-modifying therapies targeting transcription…","description":"Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer.  Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. \n\nWith a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. \n\nWe know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. \n\nWith our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.\n\nAltay Therapeutics is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.altaytherapeutics.com/","is_stealth":false,"normalized_domain":"altaytherapeutics.com","normalized_url_key":"altaytherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/altay-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:29:27.996Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","AI-powered Drug Discovery","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Altay Therapeutics — Altay develops disease-modifying therapies targeting transcription… (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Altay Therapeutics Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:29:27.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:29:27.996Z","updated_at":"2026-09-03T06:29:27.996Z"}},{"listing_type":"company","name":"General Proximity","slug":"general-proximity","tagline":"The next generation of induced-proximity medicines.","description":"The next generation of induced-proximity medicines.\n\nGeneral Proximity is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.generalproximity.bio/","is_stealth":false,"normalized_domain":"generalproximity.bio","normalized_url_key":"generalproximity.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b5e039898073137983f2b9b975353c2be69220f5.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/general-proximity","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.generalproximity.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.generalproximity.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:29:27.663Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Biotech","Drug discovery"],"one_liner_for_search":"General Proximity — The next generation of induced-proximity medicines. (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Weatherwax Bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:29:27.663Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:29:27.663Z","updated_at":"2026-09-03T06:29:27.663Z"}},{"listing_type":"company","name":"Abalone Bio","slug":"abalone-bio","tagline":"We create activating antibodies to treat diseases others can’t.","description":"Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. \n\n+ High throughput experimental measurement uniquely leverages AI/ML:  We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs)\n\n+ Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech.\n\n+ Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. \n\n+ Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.\n\nAbalone Bio is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.abalonebio.com/","is_stealth":false,"normalized_domain":"abalonebio.com","normalized_url_key":"abalonebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e9f1d41bc9bfabd8ecaa9963112dc25b23472f0a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/abalone-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.abalonebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.abalonebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Machine Learning","Synthetic Biology","Therapeutics","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:27:15.102Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Machine Learning","Synthetic Biology","Therapeutics","Drug discovery"],"one_liner_for_search":"Abalone Bio — We create activating antibodies to treat diseases others can’t. (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 14","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Abalone Bio, Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:27:15.102Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"machine-learning","name":"Machine Learning","note":null,"profile_url":"/industries/machine-learning"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:27:15.102Z","updated_at":"2026-09-03T06:27:15.102Z"}},{"listing_type":"company","name":"Sequence Bio","slug":"sequence-bio","tagline":"Discovering the true signals of disease to power life-changing drugs.","description":"90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.\n\nSequence Bio is a Y Combinator company (Summer 2019). YC-listed status: Active.","url":"https://www.sequencebio.com/","is_stealth":false,"normalized_domain":"sequencebio.com","normalized_url_key":"sequencebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/819f850ae7a7b60333fcb1b8a2c4ef4e8a3d2fd3.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/sequence-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.sequencebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.sequencebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Genomics","Therapeutics","Drug discovery"],"stage":null,"founded_year":null,"location":"St. John's, NL, Canada","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:26:39.301Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2019","Genomics","Therapeutics","Drug discovery"],"one_liner_for_search":"Sequence Bio — Discovering the true signals of disease to power life-changing drugs. (Y Combinator Summer 2019)","canonical_facts":["Y Combinator batch: Summer 2019","YC company status: Active","Team size (per YC directory): 52","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): Canada, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:26:39.301Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:26:39.301Z","updated_at":"2026-09-03T06:26:39.301Z"}},{"listing_type":"company","name":"GEn1E Lifesciences","slug":"gen1e-lifesciences","tagline":"AI platform accelerating therapies for rare & inflammatory diseases.","description":"GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). \n \nGEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.\n \nWith ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.\n \nThe team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.\n\nGEn1E Lifesciences is a Y Combinator company (Summer 2019). YC-listed status: Active.","url":"https://www.gen1e.com/","is_stealth":false,"normalized_domain":"gen1e.com","normalized_url_key":"gen1e.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gen1e-lifesciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.gen1e.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.gen1e.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Artificial Intelligence","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:24:10.798Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2019","Artificial Intelligence","Biotech","Healthcare","Drug discovery"],"one_liner_for_search":"GEn1E Lifesciences — AI platform accelerating therapies for rare & inflammatory diseases. (Y Combinator Summer 2019)","canonical_facts":["Y Combinator batch: Summer 2019","YC company status: Active","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Gen1E Lifesciences, Inc., Gen1E Lifesciences","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:24:10.798Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:24:10.798Z","updated_at":"2026-09-03T06:24:10.798Z"}},{"listing_type":"company","name":"Encepheal Therapeutics","slug":"encepheal-therapeutics","tagline":"EncepHeal develops medications to treat substance abuse, starting…","description":"EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments.\n\nOur small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. \n\nOur management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest.\n\nOur team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.\n\nEncepheal Therapeutics is a Y Combinator company (Summer 2019). YC-listed status: Inactive.","url":"http://encepheal.com/","is_stealth":false,"normalized_domain":"encepheal.com","normalized_url_key":"encepheal.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e2254c6db4aca1a94f4c379b3299c517203af457.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/encepheal-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"http://encepheal.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"http://encepheal.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Drug discovery"],"stage":null,"founded_year":null,"location":"Winston-Salem, NC, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:23:29.028Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2019","Therapeutics","Drug discovery"],"one_liner_for_search":"Encepheal Therapeutics — EncepHeal develops medications to treat substance abuse, starting… (Y Combinator Summer 2019)","canonical_facts":["Y Combinator batch: Summer 2019","YC company status: Inactive","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:23:29.028Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:23:29.028Z","updated_at":"2026-09-03T06:23:29.028Z"}},{"listing_type":"company","name":"LEAH Labs","slug":"leah-labs","tagline":"Living therapies for pets first, and their people next","description":"LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective \"full stack\" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.\n\nLEAH Labs is a Y Combinator company (Winter 2019). YC-listed status: Active.","url":"https://leahlabs.com/","is_stealth":false,"normalized_domain":"leahlabs.com","normalized_url_key":"leahlabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/6907f0370b96042be3d0036ddc25c34015a02b50.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/leah-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://leahlabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://leahlabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","CRISPR","Cell Therapy","Drug discovery"],"stage":null,"founded_year":null,"location":"Minneapolis, MN, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:19:07.483Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2019","CRISPR","Cell Therapy","Drug discovery"],"one_liner_for_search":"LEAH Labs — Living therapies for pets first, and their people next (Y Combinator Winter 2019)","canonical_facts":["Y Combinator batch: Winter 2019","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Lifengine Animal Health Laboratories, Incorporated","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:19:07.483Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:19:07.483Z","updated_at":"2026-09-03T06:19:07.483Z"}},{"listing_type":"company","name":"Oncobox","slug":"oncobox","tagline":"Finding the right cancer drug for each patient.","description":"Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%.\n\nHow does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs.\n\nOncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient.\n\nWe actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. \n\nOur team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.\n\nOncobox is a Y Combinator company (Summer 2017). YC-listed status: Active.","url":"https://oncobox.com/","is_stealth":false,"normalized_domain":"oncobox.com","normalized_url_key":"oncobox.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/oncobox","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://oncobox.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://oncobox.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Diagnostics","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"Walnut, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:09:35.609Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2017","Drug discovery","Oncology"],"one_liner_for_search":"Oncobox — Finding the right cancer drug for each patient. (Y Combinator Summer 2017)","canonical_facts":["Y Combinator batch: Summer 2017","YC company status: Active","Team size (per YC directory): 11","YC industry: Healthcare","YC subindustry: Healthcare / Diagnostics","Former names: Oncobox, OncoBox","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:09:35.609Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:09:35.609Z","updated_at":"2026-09-03T06:09:35.609Z"}},{"listing_type":"company","name":"Synvivia","slug":"synvivia","tagline":"Synvivia applies chemical control over cell behavior","description":"Synvivia applies chemical control over cell behavior. This allows us to optimize biomanufacturing of high-value biopharmaceutical products.\n\nSynvivia is a Y Combinator company (Summer 2016). YC-listed status: Active.","url":"https://www.synvivia.com/","is_stealth":false,"normalized_domain":"synvivia.com","normalized_url_key":"synvivia.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/4447def03db194c618a13840346e31a2394d316e.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/synvivia","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.synvivia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.synvivia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Industrial Bio","Artificial Intelligence","Synthetic Biology","Biotech","Manufacturing","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Berkeley, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:03:24.766Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2016","Artificial Intelligence","Synthetic Biology","Biotech","Manufacturing","Drug discovery"],"one_liner_for_search":"Synvivia — Synvivia applies chemical control over cell behavior (Y Combinator Summer 2016)","canonical_facts":["Y Combinator batch: Summer 2016","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Industrial Bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:03:24.766Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"industrial-bio","name":"Industrial Bio","note":null,"profile_url":"/industries/industrial-bio"},{"kind":"industry","slug":"manufacturing","name":"Manufacturing","note":null,"profile_url":"/industries/manufacturing"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:03:24.766Z","updated_at":"2026-09-03T06:03:24.766Z"}},{"listing_type":"company","name":"Numerion Labs","slug":"numerion-labs","tagline":"Artificial intelligence for drug discovery.","description":"Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.\n\nNumerion Labs is a Y Combinator company (Winter 2015). YC-listed status: Active.","url":"https://numerionlabs.ai/","is_stealth":false,"normalized_domain":"numerionlabs.ai","normalized_url_key":"numerionlabs.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/c3b218096497a702becc32895ca1b21c4cae78bd.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/numerion-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://numerionlabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://numerionlabs.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Deep Learning","Biotech","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T05:53:03.969Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2015","AI-powered Drug Discovery","Deep Learning","Biotech","Drug discovery","Oncology"],"one_liner_for_search":"Numerion Labs — Artificial intelligence for drug discovery. (Y Combinator Winter 2015)","canonical_facts":["Y Combinator batch: Winter 2015","YC company status: Active","Team size (per YC directory): 67","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Atomwise","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T05:53:03.969Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-learning","name":"Deep Learning","note":null,"profile_url":"/industries/deep-learning"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T05:53:03.969Z","updated_at":"2026-09-03T05:53:03.969Z"}}],"total":35,"limit":50,"offset":0}